Preobrazhenskiĭ D V, Nekrasova N I, Khoseva E N, Arystanova A, Talyzina I V, Pataraia S A
Kardiologiia. 2011;51(4):67-73.
Torasemide is a loop diuretic and has been used for the treatment of both acute and chronic congestive heart failure (CHF) and arterial hypertension (AH). Torasemide is similar to other loop diuretics in terms of its mechanism of diuretic action. It has higher bioavailability (>80%) and a longer elimination half-life (3 to 4 hours) than furosemide. In the treatment of CHF torasemide (5 to 20 mg/day) has been shown to be an effective diuretic. Non-diuretic dosages (2.5 to 5 mg/day) of torasemide have been used to treat essential AH, both as monotherapy and in combination with other antihypertensive agents. When used in these dosages, torasemide lowers diastolic blood pressure to below 90mm Hg in 70 to 80% of patients. Antihypertensive efficacy of torasemide is similar to that of thiazides and related compounds. Thus low-dose torasemide constitutes an alternative to thiazides in the treatment of essential AH.
托拉塞米是一种袢利尿剂,已用于治疗急慢性充血性心力衰竭(CHF)和动脉高血压(AH)。托拉塞米在利尿作用机制方面与其他袢利尿剂相似。它的生物利用度较高(>80%),消除半衰期(3至4小时)比呋塞米长。在CHF治疗中,托拉塞米(5至20毫克/天)已被证明是一种有效的利尿剂。托拉塞米的非利尿剂量(2.5至5毫克/天)已用于治疗原发性AH,既作为单一疗法,也与其他抗高血压药物联合使用。当以这些剂量使用时,托拉塞米可使70%至80%的患者舒张压降至90毫米汞柱以下。托拉塞米的抗高血压疗效与噻嗪类及相关化合物相似。因此,低剂量托拉塞米在原发性AH治疗中可作为噻嗪类药物的替代药物。